ImmunityBio (IBRX) Asset Writedowns and Impairment (2014 - 2023)

ImmunityBio (IBRX) has 4 years of Asset Writedowns and Impairment data on file, last reported at $886000.0 in Q4 2023.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $886000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$9.8 million (changed N/A YoY) and the FY2023 annual result came in at $886000.0, up 30.1% from the prior year.
• Asset Writedowns and Impairment grew to $886000.0 in Q4 2023 per IBRX's latest filing, from -$10.7 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $10.7 million in Q3 2020 and bottomed at -$10.7 million in Q4 2020.
• The 3-year median for Asset Writedowns and Impairment is $805000.0 (2019), against an average of $402500.0.
• Peak annual rise in Asset Writedowns and Impairment reached 1572.38% in 2020, while the deepest fall reached 1572.38% in 2020.
• Tracing IBRX's Asset Writedowns and Impairment over 3 years: stood at $724000.0 in 2019, then tumbled by 1572.38% to -$10.7 million in 2020, then jumped by 108.31% to $886000.0 in 2023.
• Per Business Quant, the three latest IBRX Asset Writedowns and Impairment figures stand at $886000.0 (Q4 2023), -$10.7 million (Q4 2020), and $10.7 million (Q3 2020).

Peer Comparison